Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Related Keywords

Massachusetts ,United States ,Jaime Schneider ,Harvard Medical School ,Thoracic Cancers ,Massachusetts General Hospital ,Osimertinib ,Egfr Mutant Non Small Cell Lung Cancer ,